Due to a high probability of malignancy in patients with positive serum anti-TIF1γ antibodies, an extensive workup for malignancy should be carried out after diagnosis of anti-TIF1γ-positive dermatomyositis [9,15]. Here, TRIM33 is linked to dermatomyositis.